Intercept Pharmaceuticals

Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Thu, 01/19/23 - 09:39 am
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
In another blow to Intercept, the FDA is investigating Ocaliva for potential risk of liver disorder
Endpoints
Fri, 10/9/20 - 10:48 am
FDA
Intercept Pharmaceuticals
Ocaliva
NASH
FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines
Endpoints
Mon, 06/29/20 - 10:06 am
Intercept Pharmaceuticals
NASH
FDA
obeticholic acid
Gilead/Galapagos, Intercept and Corbus trials could be hit by coronavirus spread: analyst
Fierce Biotech
Wed, 03/11/20 - 10:55 am
clinical trials
Gilead Sciences
Galapagos
Corbus Pharmaceuticals
Intercept Pharmaceuticals
coronaviruses
COVID-19
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
BioSpace
Mon, 01/13/20 - 11:08 am
JPMHC 2020
M&A
Exelixis
Intercept Pharmaceuticals
Avidity Biosciences
Theravance
Moderna Therapeutics
Kodiak Sciences
Intercept's NASH decision delayed by FDA, but don't panic: analysts
Fierce Pharma
Mon, 12/16/19 - 10:31 am
Intercept Pharmaceuticals
NASH
obeticholic acid
FDA
2 NASH drugmakers have wildly different Mondays
Biopharma Dive
Mon, 11/25/19 - 10:11 pm
Intercept Pharmaceuticals
CymaBay Therapeutics
FDA
NASH
seladelpar
obeticholic acid
These 6 biotech stocks are promising takeover targets
Marketwatch
Thu, 05/2/19 - 11:33 am
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
Intercept Tries to Outrun Pharma in Race for the Next Blockbuster
Bloomberg
Thu, 04/11/19 - 07:27 pm
liver disease
NASH
Intercept Pharmaceuticals
OCA
obeticholic acid
2 Biotechs With Big Dates in April
Motley Fool
Sat, 03/30/19 - 01:04 pm
Alnylam
EASL
Intercept Pharmaceuticals
Onpattro
givosiran
NASH
Ocaliva
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
BioSpace
Tue, 02/19/19 - 10:24 am
NASH
Intercept Pharmaceuticals
obeticholic acid
OCA
clinical trials
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
CP Wire
Thu, 04/5/18 - 04:01 pm
Intercept Pharmaceuticals
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
Wed, 07/5/17 - 07:08 pm
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
Could These 2 Small Biotechs Beat Allergan and Gilead Sciences?
Motley Fool
Sat, 12/17/16 - 12:23 pm
biotech
Allergan
Gilead Sciences
Genfit
Intercept Pharmaceuticals
NASH
Seven $1 billion-plus drugs seen reaching market in 2016
Yahoo/Reuters
Thu, 02/4/16 - 09:29 am
Intercept Pharmaceuticals
Gilead Sciences
Roche
AbbVie
Merck
obeticholic acid
emtricitabine
2015's Worst Clinical Failures
Motley Fool
Sat, 12/12/15 - 02:01 pm
clinical trials
liver disease
cancer pain
Eli Lilly
Intercept Pharmaceuticals
GW Pharma
Intercept's much-hyped NASH drug misses the mark in Phase II
Fierce Biotech
Wed, 10/28/15 - 09:23 am
Intercept Pharmaceuticals
NASH
Sumitomo Dainippon
Japan
OCA
5 Biotech Stocks On Deck With The FDA
Yahoo/Benzinga
Tue, 06/30/15 - 06:13 pm
FDA
Alnylam
Patisiran
Esperion Therapeutics
ETC-1002
Intercept Pharmaceuticals
obeticholic acid
Sarepta Therapeutics
eteplirsen
Tekmira
TKM-PLK1

Pages